Clinical Trials Logo

Vaccination Failure clinical trials

View clinical trials related to Vaccination Failure.

Filter by:

NCT ID: NCT05923970 Not yet recruiting - Clinical trials for Vaccine Response Impaired

Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?

Start date: September 1, 2024
Phase:
Study type: Observational

The current recommendation for a full course of measles-mumps-rubella-(varicella) vaccine (MMR(V)) is two doses. The problem is, many individuals within the vaccinated cohort show antibody levels that are below the level considered to be protective, even after two doses of vaccine. Because of these waning antibody levels, it is currently unknown whether highly vaccinated populations are protected from infection against measles, mumps, rubella, or varicella should they be exposed to any of these viruses. The uncertainty of a woman's immune status is partly due to the type of testing that is used to indicate protection. While immunity to viral infection requires both a humoral and a cell mediated immune (CMI) response, only humoral (antibody) responses are measured routinely in the laboratory. This study will examine CMI responses and the role of a third dose of vaccine for previously vaccinated women whose antibody levels are below the cut off. This study will not administer vaccine, but rather will include women who have received a third dose of vaccination through routine health care follow up in the study cohort.

NCT ID: NCT05266664 Recruiting - Preterm Clinical Trials

Preterm Immune System Development and Response to Immunization

PRIMI
Start date: December 8, 2022
Phase:
Study type: Observational

In this study the response to vaccination and development of the immune system in very preterm infants upon the current vaccination schedule will be compared to healthy term infants.

NCT ID: NCT05050461 Not yet recruiting - Clinical trials for Non-hodgkin Lymphoma,B Cell

Immune Response After SARS-CoV-2 Vaccination in a Context of Non-Hodgkin Lymphoma

LYMPHO-CoVac
Start date: September 20, 2021
Phase: N/A
Study type: Interventional

The specific immune response to SARS-CoV-2 includes a humoral response - specific IgM appearing 5 days after the onset of symptoms while IgG appears after 14 days - and a T lymphocyte component, with specific activated CD8 and CD4 T lymphocytes (Dan JM et al., Science 2021). Mortality from infection varies greatly depending on the age of the affected subjects and their comorbidities including a history of cancer (Liang W et al, 2020). Among these cancers, a history of malignant hemopathy in the 5 years preceding the onset of Covid-19 increases the risk of death by a factor of 3 (OpenSAFELY collaborative 2020). Among them, lymphoid hemopathies induce hypogammaglobulinemia and / or lymphopenia. These factors combined with chemotherapy and immunotherapy treatments promote the development of infections in affected individuals. Among these, are the anti-CD20 monoclonal antibodies, widely prescribed for treating B-cell non-Hodgkin lymphomas (B-NHL). They induce a deep and lasting B-cell lymphopenia, which can promote infections (Maschmeyer G et al, 2019). They reduce the production of antibodies and the constitution of memory responses to a new pathogen or to a vaccination. In addition, B lymphocytes likely have a key immunomodulatory role in the control of viral infections. We conducted a retrospective study in 89 patients with lymphoma and Covid-19 after the first phase of the epidemic in different centers in the Île-de-France and eastern France regions (Lamure S et al. , 2020). With a 6-month follow-up, we showed a pejorative prognostic impact of anti-CD20 monoclonal antibody treatment on Covid-19-related mortality (Duléry et al, 2021). Vaccination of these at-risk patients is therefore essential. A growing concern is how patients with B-NHL who have been vaccinated with a SARS-CoV-2 mRNA vaccine are protected against infection, depending on whether or not they have received anti-CD20 monoclonal drugs and / or chemotherapy. Knowing the medium-term immunological evolution after vaccination against SARS-CoV-2 in patients with B-cell NHL is necessary in order to be able to adapt the therapeutic and vaccine recommendations. The main objective of this study is to determine how recent treatment (in the year before vaccination) with anti-CD20 monoclonal antibody modifies the immune response after vaccination against SARS-CoV-2 in adults with B-NHL compared to patients who have not recently been exposed to this immunotherapy.

NCT ID: NCT05028322 Not yet recruiting - Cirrhosis, Liver Clinical Trials

Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen

IDMODVHB
Start date: November 1, 2021
Phase: Phase 2
Study type: Interventional

In a population of cirrhotics patients who did not responde to an anti-HBV vaccination according to the recommended vaccination, the goal is to : Describe the proportion of patients with HBs antibody levels greater than 10mUI/mL at 1 month of the last injection of vaccine ; with a M0-M1-M6 vaccine regimen using 3 vaccines strategies : - After simple intramuscular vaccine (IM) ( Control group ) - After simple intradermal vaccine - after IMIQUIMOD's application followed by intradermal vaccine administration The main hypothesis of this study is : IMIQUIMOD acts as an immunity booster, so the combination of IMIQUIMOD with an intra-dermal injection of the anti-HBV vaccine allows better acquisition of post-vaccination immunization.

NCT ID: NCT03792022 Not yet recruiting - Vaccination Failure Clinical Trials

Timeliness and Completeness of Routine Childhood Vaccinations by 2 Years of Age in Nigeria.

Start date: January 10, 2019
Phase:
Study type: Observational

The timeliness of routine childhood immunization should be an important component in measuring vaccination coverage rates especially in LMIC countries like Nigeria, yet this is overlooked. This study will determine the age- specific immunization timely uptake rates for the various vaccines covered in the routine childhood immunization and seek out factors that affect timely vaccine uptake among Nigerian children.

NCT ID: NCT03683732 Completed - Vaccination Failure Clinical Trials

EXTENSION OF THE EUROPEAN E-BUG PROJECT

Ext EBUG
Start date: March 1, 2013
Phase:
Study type: Observational [Patient Registry]

Bacterial resistance to antibiotics is a growing concern in Europe, vaccination coverage is inadequate, and young adults, who are the highest antibiotic consumers, have the lowest level of knowledge. Extension of the e-Bug project, a European educational school programme concerning microbes, antibiotics and vaccination, to 15-18-year-olds implies the development of educational resources based on social marketing to promote sustainable behavioural changes. The objectives of the present study, which is part of the needs assessment in France, are to explore the attitudes, knowledge and behaviour of 15-18-year-olds concerning antibiotics and vaccination and their health education needs. Individual semi-structured interviews were conducted using purposeful sampling of 15- to 18-year-olds, until data saturation, and were transcribed and analysed.

NCT ID: NCT01908946 Unknown status - Vaccination Failure Clinical Trials

Automated SMS Reminders to Parents on Their Cell Phones Can Significantly Improve the on Time Vaccination Rates Children in Pakistan

Start date: May 2013
Phase: N/A
Study type: Interventional

The investigators plan to test the effectiveness of reminders to parents/guardians on cell phones through short messaging system (SMS) in improving the on-time routine immunization for children in Pakistan. SMS message as a reminder tool can be very effective in health care settings at public health scale. This study will be conducted in an urban- squatter settlement area, Ibrahim Haidry union council in Karachi. Parents/guardians of children randomized in intervention arm will be sent SMS reminders vaccination visit reminders at 6, 10 and 14 weeks of life.

NCT ID: NCT01859546 Recruiting - Vaccination Failure Clinical Trials

SMS Reminders to Improve the on Time Vaccination Rates Among Children in Pakistan

Start date: March 2013
Phase: N/A
Study type: Interventional

Vaccines are one of the best public health tools available to achieve the Millennium Development Goal (MDG) # 4 of decreasing child mortality. A major reason for poor childhood vaccine coverage is the lack of awareness among parents regarding the need for immunization in children, and the importance of completing the entire series of vaccines. This result in significant drop-out between vaccines delivered at birth and later in the infancy period. New innovative methods involving technologies are needed to be employed to increase the vaccine coverage. This study is being conducted in Karachi, Pakistan and main study objective is • To assess the effectiveness of SMS reminders on cell phones in improving the compliance of subsequent visits for routine immunization for children.

NCT ID: NCT01807780 Completed - Vaccination Failure Clinical Trials

Safety, Immunogenicity And Efficacy Of Vaccination In Military Personnel

Start date: September 2012
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if multiple vaccination in military personnel may be correlated with the appearance of poorly defined diseases as symptomatic multisyndrome, autoimmune or lymphoproliferative disorders. At the same time, considering possible interference between different vaccines, proteins and polysaccharides, living and inactivated, the study aims to assess the immunogenicity and efficacy also in relation to the specific Human Leucocyte Antigens (HLA) genetic structure.

NCT ID: NCT01548326 Enrolling by invitation - Hepatitis B Clinical Trials

Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine

Start date: September 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether short-term Atorvastatin can increase the immunity response to hepatitis B vaccination in vaccine Nonresponders.